Deltagen, Inc. engages in the provision of drug discovery tools and services to the biopharmaceutical industry. The company is headquartered in San Carlos, California. The company went IPO on 2000-08-03. The firm offers a suite of programs designed to manage the efficiency of drug discovery, including access to biological models, as well as both small-molecule and secreted protein drug targets. In addition, it offers target validation data in the areas of immunology and metabolic diseases. The firm's biology approach is designed to help clear the first and major hurdle of drug target discovery: lead validation. Its DeltaBase is a searchable database of in vivo-derived mammalian gene function information and gene targets. DeltaOne from the Company provides per-gene access to the knockout mice and/or phenotypic data needed.
How did DGEN's recent EPS compare to expectations?
The most recent EPS for Deltagen Inc is $, expectations of $.
How did Deltagen Inc DGEN's revenue perform in the last quarter?
Deltagen Inc revenue for the last quarter is $
What is the revenue estimate for Deltagen Inc?
According to of Wall street analyst, the revenue estimate of Deltagen Inc range from $ to $
What's the earning quality score for Deltagen Inc?
Deltagen Inc has a earning quality score of B+/57.914906. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Deltagen Inc report earnings?
Deltagen Inc next earnings report is expected in
What are Deltagen Inc's expected earnings?
Deltagen Inc expected earnings is $, according to wall-street analysts.